Department of Health written question – answered at on 27 July 2015.
To ask Her Majesty’s Government whether NHS patients will be able to access Nivolumab on the Cancer Drugs Fund while the National Institute for Health and Care Excellence concludes single technology appraisals of the drug for the treatment of melanoma, non-squamous lung cancer and squamous lung cancer.
To ask Her Majesty’s Government what plans they have to provide alternative means of funding immuno-oncology treatments, while awaiting a decision by the National Institute for Health and Care Excellence in the light of the suspension of new applications to the Cancer Drugs Fund.
In the absence of guidance from the National Institute for Health and Care Excellence, it is for commissioners to make funding decisions on new drugs and treatments based on the available evidence.
Yes0 people think so
No0 people think not
Would you like to ask a question like this yourself? Use our Freedom of Information site.